Highlights

• Breakthrough nanoradiopharmaceutical using Lutetium-177 achieves 84% tumor recurrence suppression in gastric cancer through dual-action theranostics that enables surgeons to visualize tumors via fluorescence while simultaneously destroying microscopic cancer remnants with targeted radiation.
• Global Lutetium-177 supply chain stabilizes after 2023-2024 shortages, with European facilities like IRE Belgium and Curium Pharma expanding production to meet surging demand from expanding clinical trials beyond prostate and neuroendocrine cancers to breast, lung, and pancreatic tumors.
• Next-generation radioisotopes like Terbium-161 emerge from Swiss research institutions as more precise alternatives to Lutetium-177, capable of targeting single-cell micro-metastases through Auger electron emission for enhanced cancer treatment precision.

---

The most electrifying news for the medical sector arrived via the Journal of the American Chemical Society. Researchers have unveiled a breakthrough in what is known as "nanoradiopharmaceuticals," specifically a new weapon against gastric cancer that utilizes the Rare Earth isotope Lutetium-177. To understand the significance of this, one must look past the complex chemistry and look at the method, which oncologists call "Theranostics."

This portmanteau of therapy and diagnostics represents a shift from the old "trial and error" approach to medicine toward precision engineering. The new innovation acts as a microscopic "double agent." It uses a Lanthanide-based fluorescent signal to make tumor cells literally glow in the Near-Infrared spectrum, allowing surgeons to see and remove the bulk of the cancer with unprecedented precision. Simultaneously, the particle carries a payload of radioactive Lutetium-177 to hunt down and destroy any microscopic remnants the surgeon might miss.

In preclinical trials, this "see and destroy" approach suppressed tumor recurrence by 84%. But for the investor and the industry observer, the excitement of the lab must be weighed against the realities of the supply chain.

While this specific gastric cancer treatment is still years away from human application, the isotope driving it, Lutetium-177, is already the gold standard in modern radiotherapy. The market for this isotope is currently in a delicate balance. Following the severe shortages of 2023 and 2024, production capacity has expanded significantly, with major reactors in China and Europe coming online. Yet, demand is surging in tandem with supply.

Europe plays a pivotal role in Lutetium-177 production, addressing past shortages through dedicated facilities. The Institute for Radio Elements (opens in a new tab) (IRE) in Fleurus, Belgium, operates a key cyclotron-based production line, supplying non-carrier-added Lutetium-177 for clinical use across the continent.

Additionally, Curium Pharma, (opens in a new tab) with sites in the Netherlands and France, has scaled up reactor production at facilities like the HFR reactor in Petten, Netherlands, contributing to over 20% of global supply by late 2025. These efforts, supported by the European Commission's Horizon Europe funding, ensure reliable sourcing for theranostics, with exports to the U.S. and Asia stabilizing prices.

We are witnessing a massive expansion of clinical trials that is soaking up this new capacity. We are moving beyond the niche treatment of neuroendocrine tumors or prostate cancer. New trials, such as the "LuMIERE" study (opens in a new tab), are currently recruiting patients to test Lutetium-177 on tumors expressing Fibroblast Activation Protein (FAP). If successful, this would open the door to treating a vast array of solid tumors including breast, lung, and pancreatic cancers. Effectively blowing the ceiling off the total addressable market for medical Rare Earths.

For gastric cancer specifically, early-phase trials like those evaluating Lutetium-177-FAP-2286 in advanced solid tumors, including gastric subtypes, are led by Novartis in collaboration with European centers such as University Hospital Zurich, Switzerland (opens in a new tab). These studies report good tolerability, with doses up to 9.9 GBq showing no severe adverse events in initial cohorts of 11 patients. The broader COMPETE Phase III trial, executed by ITM Isotope Technologies Munich (Germany) across 84 sites (32 in Europe), tests Lutetium-177-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumors, achieving a median progression-free survival extension of nearly 10 months as of 2025 data.

Furthermore, innovation is not stopping at Lutetium. In Switzerland, hubs like the Paul Scherrer Institute (opens in a new tab) and University Hospital Basel (opens in a new tab) are already pioneering the "next" Lutetium: Terbium-161.

This isotope acts as a sharper scalpel, emitting Auger electrons that can target single-cell micro-metastases that Lutetium might miss.

1. https://pmc.ncbi.nlm.nih.gov/articles/PMC11002837/ (opens in a new tab)
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC9418400/ (opens in a new tab)
3. https://www.itm-radiopharma.com/news/press-releases/press-releases-detail/itm-presents-positive-topline-phase-3-compete-trial-data-with-nca-177lu-edotreotide-itm-11-a-targeted-radiopharmaceutical-therapy-in-patients-with-grade-1-or-2-gastroenteropancreatic-neuroendocrine-tumors-at-the-enets-2025-conference-688/ (opens in a new tab)
4. https://pmc.ncbi.nlm.nih.gov/articles/PMC11074414/ (opens in a new tab)
5. https://ecancer.org/en/news/27163-esmo-2025-research-targets-treatment-resistance-in-neuroendocrine-tumours (opens in a new tab)
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC9399464/ (opens in a new tab)
7. https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(25)00170-X/fulltext (opens in a new tab)
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC4048749/ (opens in a new tab)
9. https://pubmed.ncbi.nlm.nih.gov/40186126/ (opens in a new tab)
10. https://stanislavkondrashov.ch/the-role-of-rare-earths-in-medical-imaging-technologies-by-stanislav-kondrashov/ (opens in a new tab)